SOFIE CO. - RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

PIID: HT009026FG1210062

Signed Date: Dec 2, 2025Effective Date: Dec 2, 2025End Date: Closes in 115 days

Award $

$25K

Vendor

SOFIE CO.

NAICS

325412

Signed Date

Dec 2, 2025

Key Details

Dollars Obligated

$25,261.04

Base & All Options

$25,261.04

Awarding Agency

Department of Defense

Awarding Sub-Agency

Defense Health Agency

NAICS Code

325412 - PHARMACEUTICAL PREPARATION MANUFACTURING

Product Service Code

6640 - LABORATORY EQUIPMENT AND SUPPLIES

Extent Competed

COMPETED UNDER SAP

Number of Offers

Place of Performance

STERLING, VA, 201662499, CD-VA-10

Description

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

Context & Analysis

On Dec 2, 2025, Department of Defense obligated $25,261.04 to SOFIE CO. for radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: competed under sap with 2 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in STERLING, VA. The contract is scheduled through Sep 30, 2026 — approximately 4 months remaining.